The therapeutic model we are employing envisages the surgical implementation of the Sinnais implantable pump technology in the chest cavity or abdominal cavity, with a catheter routed to a specific site identified by the disease location in order to deliver drugs continuously. Sinnais will enable the delivery of a medicating agent at a substantially lower level than the [simple_tooltip content=’The highest dose of a drug or treatment that does not cause unacceptable side effects.’]Maximum Tolerated Dose[/simple_tooltip]. Depending on the individual circumstance of the patient, this delivery can be sustained for a continuous periods. At the same time, Sinnais can collect specific biomarkers related to the patient’s specific disease model.
For example, one of the sensory elements forming the homeostatic loop governing the behavior of the pump is a biosensor which detects and counts the amounts of a biomarker protein such as Vascular Endothelial Growth Factor (VEGF) molecules per unit of volume continuously present in the bloodstream. In this example, the amount of VEGF present in the bloodstream of a healthy patient is an order of magnitude lower than the amount present in a patient with a tumor mass in a malignant state. Therefore, a detection of a high VEGF level output emanating from our biosensor built into Sinnais is able to alert the physician that the patient is not responding to the current composition of the medication being prescribed.
NEXT: Homeostatic Loop